Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR — K.J. Mason (2018) | RDL Network
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR
Article 2018 en
Authors
KM
K.J. Mason
JB
Juliet N. Barker
CS
Catherine Smith
Abstract
1 min read
Clinical trial effectiveness and safety outcomes are not representative of real-world patients in BADBIR patients categorized as ineligible for such trials.
K.J. Mason, Juliet N. Barker, Kay Hogan Smith, Philip Hampton, Mark Lunt, Kathleen McElhone, Richard Warren, Zenas Z N Yiu, Christopher Em Griffiths, A. David Burden
Zenas Z N Yiu, K.J. Mason, Juliet N. Barker, Philip Hampton, Kathleen McElhone, Catherine Smith, Richard B. Warren, Christopher Em Griffiths, Mark Lunt, A. David Burden
Zenas Z N Yiu, G Becher, Brian Kirby, Philip Laws, Nick J. Reynolds, Catherine Smith, Richard B. Warren, Christopher Em Griffiths, Fiona Browne, Ian Evans, Elise Kleyn, Linda Lawson, Kathleen McElhone, Teena Mackenzie, Tess McPherson, Ruth Murphy, Caroline Owen, Eleanor Pearson, Josh Richards, Mark Lunt, A. David Burden, Oras Alabas,
Andrés Yarur, Gerassimos J. Mantzaris, Mark S. Silverberg, Margaret Walshe, Petros Zezos, Dan Joseph Stein, M Bassel, T Lissoos, Claudia Lopez, Athanasios Natsios, Gabriela Radulescu, Haridarshan Patel, Dirk Demuth, Brian Bressler
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.